Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432274 · ClinicalTrials.gov registry record · Phase 1
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
A Phase 1 study, sponsored by Eisai Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
NCT02432274: Completed Phase 1 study, sponsored by Eisai Limited.
NCT02432274 is a Phase 1 study that has completed, run by Eisai Limited. The registered enrollment target is 117 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02432274, a Phase 1 study, has completed, sponsored by Eisai Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
Study Summary
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid malignancies including differentiated thyroid carcinoma (single agent lenvatinib) and osteosarcoma (single agent and combination lenvatinib).
Interventions
- DRUG Lenvatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2014-12-29 |
| Est. Completion | 2022-07-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02432274
The ClinicalTrials.gov registry entry for NCT02432274 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenvatinib is the first listed.
NCT02432274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02432274 about?
NCT02432274 is a clinical study titled "Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma". This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid malignancies including differentiated thyroid carcinoma (single agent l...
What is the current status of trial NCT02432274?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2014-12-29. Estimated completion is 2022-07-20.
What interventions are being tested in trial NCT02432274?
The interventions under investigation include: Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT02432274?
This trial is sponsored by Eisai Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.